Ambler PA, April 24, 2017 - Moberg ICU Solutions (Ambler, PA) has received an initial $3 million investment from Micromed SAS a wholly owned subsidiary of ArchiMed, Europe’s first independent private equity fund focused exclusively on the healthcare sector. Funds will be used to support product sales and continued innovation in the precision management of patients with brain injuries in critical care.
Moberg’s Component Neuromonitoring System (CNS) works together with the vital signs monitor and other medical devices to provide a comprehensive view of brain dynamics promoting timely intervention by caregivers. The product is unique in that it is also a full-function continuous EEG machine and is the first medical device that can show the relationships between the electrical activity of the brain and other physiology at the bedside. The CNS Monitor provides clinicians with the information to personalize treatment for neurocritical care patients. The investment will provide growth capital as well as continue innovation and commercialization previously supported by the Department of Defense.
“Recent advances in the understanding of brain injury and the move towards precision medicine have greatly increased the interest in our monitoring platform. Micromed’s investment and continued support will fund the growth we are currently experiencing”, said Dick Moberg, Founder and CEO of Moberg ICU Solutions.
“We are impressed with the innovation and technology we see at Moberg ICU Solutions. Clearly, they are leading the way in transforming neurocritical care to more data-driven patient management. We are pleased to be part of supporting this success story in neurocritical care”, said Christoph Böhmer, Operating Partner and Chairman of the build up of ArchiMed in the neurodiagnostic sector.
Moberg Research, Inc. (dba Moberg ICU Solutions) is a medical device development and manufacturing company specializing in neurological patient monitoring solutions for acute care. Products are sold in the U.S., Canada, and Europe. Moberg Research was founded in 1998 and has continuously developed products that are transforming neurocritical care. For more information visit www.moberg.com.
Founded in 2014 by the global leaders of the 3i Healthcare Team, ArchiMed is a strategic and financial partner for European Healthcare companies. Moberg is the second build up investment of ArchiMed in the neurodiagnostic sector and the first in the US. For more information visit www.archimed-group.eu.
President and CEO
Moberg Research, Inc.